AstraZeneca Pharma India has notified the National Stock Exchange of India and BSE Limited of the contact details of Key Managerial Personnel authorised to determine the materiality of events and information, in compliance with SEBI’s Listing Obligations and Disclosure Requirements Regulations 2015.
The company designated three senior executives for this responsibility. Mr Praveen Rao Akkinepally, Managing Director, has been authorised alongside Ms Bhavana Agrawal, Chief Financial Officer and Director, and Ms Tanya Sanish, Company Secretary and Compliance Officer.
All three officials are based at AstraZeneca’s office in India and can be reached at 080 6774 8000. Their respective email addresses have been provided to the stock exchanges for official communication regarding materiality assessments.
The designation is made pursuant to Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which requires listed companies to identify and disclose the individuals responsible for determining whether an event or information is material enough to be disclosed to stock exchanges. This ensures transparent and timely communication with capital markets regarding significant corporate developments.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).